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Abstract
Background Psoriatic arthritis (PsA) is a variable and
complex inflammatory condition. Symptoms can compro-
mise physical function, reduce quality of life, and accrue
significant health costs. Commonly used patient-reported
outcomes largely reflect the professionals’ perspective,
however it is not known whether they capture what is
important to patients.
Objective The aim of our study was to identify treatment
outcomes important to patients with PsA.
Methods Eight focus groups that were audio recorded,
transcribed, anonymised and analysed using inductive
thematic analysis were conducted at five hospital sites. The
full data set was analysed by the lead researcher, and
subsets analysed by three team members (including patient
partners).
Results Overall, 41 patients sampled for a range of phe-
notypes and domains of disease activity participated in the
study: 20 males; mean age 58 years (range 28–75, standard
deviation [SD] 11.4); mean disease duration 9 years (range
0.5–39, SD 8.3); and mean Health Assessment Question-
naire score of 1 (range 0.0–2.5, SD 0.7). Over 60 outcomes
were identified and grouped into four themes: (i) symptom
alleviation (e.g. pain, fatigue, itchy skin, swelling, and
reducing variability); (ii) reduction of disease impact (e.g.
tiredness and pain, mobility and dexterity, deteriorating
physical fitness, negative emotional responses, and strained
relationships and social interactions); (iii) improved prog-
nosis (e.g. slowing down disease progression, maintaining
independence, and enhancing quality of life); and (iv)
minimisation of treatment harm and burden (e.g. nausea,
long-term effects, and administration and monitoring of
treatments).
Conclusions Outcomes from treatments that are important
to patients, which relate to impacts from PsA and its
treatment that range beyond those outcomes commonly
measured, were identified. These patient perspectives need
to be considered when evaluating treatments.
Key Points for Decision Makers
Patients identified important outcomes beyond those
that are commonly evaluated.
There is a need to establish how identified outcomes
are represented in existing measures.
The outcomes identified reflect patients’ treatment
beliefs and influence their treatment decisions.
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1 Background
Psoriatic arthritis (PsA) is a complex inflammatory condi-
tion, comprising five phenotypes: polyarthritis,
oligoarthritis, axial, distal interphalangeal, and mutilans.
Symptoms can include a red, scaly rash (psoriasis),
inflammation of the tendons and ligaments (enthesitis),
swelling in the fingers and toes (dactylitis), stiff and painful
joints, thickening and pitting of the nails, and fatigue, and
can impair physical function, cause disability, and reduce
quality of life [1]. In addition, PsA can accrue significant
health costs. For example, up to half of patients with PsA
have some level of work disability, and three in ten are
unemployed [2].
PsA is estimated to affect 19/10,000 people in the UK
[3]. Among people with psoriasis, this increases to
approximately 10%, with higher prevalence in those with
more extensive skin disease [4]. Many treatments are
available for the management of PsA, including
methotrexate and other conventional synthetic disease-
modifying antirheumatic drugs (csDMARDs), as well as
numerous biological DMARDs (bDMARDs) [5]. The
recommended treatment target is remission or, alterna-
tively, low disease activity [6]. However, response to
treatments varies across the different manifestations of
PsA, highlighting that it is not a clinically or therapeuti-
cally homogeneous disease [7].
Many outcomes reported in relation to disease activity in
PsA reflect clinicians’ and researchers’ views about domains
which should be assessed. Moreover, the patient-reported
outcome measures (PROMs) used to capture them have typi-
cally been designed without significant input from patients
[8–10]. This is counter to recommendations and means that
research and clinical practice might fail to measure outcomes
thatmatter to patients [11].As an example, the patient-reported
core domains for PsA were peripheral joint activity, skin
activity, pain, patient global assessment, physical function, and
health-related quality of life. Only four patients contributed to
this when it was proposed at the Outcome Measures in
Rheumatology (OMERACT) Conference, therefore consen-
sus was derived largely from professional views, and
OMERACT requested further patient input [12, 13].
A PROM designed to capture PsA impact is the Psori-
atic Arthritis Impact of Disease (PsAID) questionnaire, the
development of which involved 12 patient research part-
ners from European countries who discussed the findings of
a literature review examining existing PROMs that might
capture impact. This was followed by a ranking exercise
and validation study with patients [14]. Although the
PsAID includes a patient perspective, the domains within it
were developed from the review of existing PROMs driven
by clinicians’ perspectives.
It is crucial that treatment trials measure outcomes that
are meaningful to patients. Understanding what patients
want and expect from treatment also has implications for
clinical practice. The aim of our study was to capture the
perspective of patients with PsA with regard to important
treatment outcomes. The study findings are reported in
accordance with the Consolidated Criteria for Reporting
Qualitative Research guidelines [15].
2 Methods and Patients
This study was approved by the National Research Ethics
Service Committee North West-Haydock (reference
15/NW/0609). Qualitative methods were used as the study
aimed to explore patients’ experiences and views. Focus
groups were selected for data collection because they
facilitate debate and clarify convergent and divergent
views among those taking part [16]. The focus group dis-
cussions were based on a topic guide designed by the
research team, comprising patient partners (JL, CB),
rheumatology clinical academics (WT, SH, NMH), and a
qualitative researcher (ED) (Table 1).
The research team designed a maximum variation
sampling frame to guide their recruitment strategy and
include patients with a range of age, disease duration, sex,
PsA phenotypes and domains of disease activity. Patients
were eligible to take part if they were over 18 years of age
with a clinician-confirmed diagnosis of PsA, had sufficient
English language to participate in discussions, had capacity
to give informed consent, and fulfilled the sampling frame
criteria. Recruitment was conducted at each site by local
members of the rheumatology research team. Eligible
patients were either given a study information pack when
they attended a hospital outpatient clinic, or a study
information pack was sent to them in the mail. Study
information packs included a cover letter from a clinician
in the local rheumatology team and a patient information
sheet. Prior to the start of the focus groups, patients pro-
vided written consent, demographic data (age, sex, disease
duration), information about current medications and levels
of disability (Health Assessment Questionnaire [HAQ])
[17] and answered the question ‘Are you experiencing a
flare of your psoriatic arthritis today?’, using the response
options ‘yes’, ‘no’ or ‘not sure’.
Focus groups comprising four to seven participants were
conducted in nonclinical rooms at five hospital sites in
England. They lasted between 63 and 87 min and were
cofacilitated by ED and SH, both experienced qualitative
researchers. Focus groups were audio recorded and tran-
scribed, with additional note-taking to aid transcription.
Transcripts were anonymised by replacing participants’
names with pseudonyms and removing all place names.
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Data were analysed manually using inductive thematic
analysis [18]. First, data were coded by reading transcripts
multiple times and making notes of words or short phrases
that captured what was being said in the focus groups.
Next, lists of words and short phrases from transcripts were
reduced by removing duplications. Conceptually-related
codes were then grouped together to inform overarching
themes and subthemes. This data-driven approach was used
because no ‘a priori’ theories were applied to the data. The
full data set was analysed by ED, with a subset analysed
independently by JL, CB and SH. Findings were shared,
discussed and agreed by coauthors. Thematic saturation (no
new information emerging) was achieved within six focus
groups, with the final two focus groups being confirmatory
[19].
3 Findings
Overall, 41 patients took part in eight focus groups: 20
males; mean age 58 years (range 28–75, standard deviation
[SD] 11.4); mean disease duration 9 years (range 0.5–39,
SD 8.3); and mean HAQ of 1 (range 0.0–2.5, SD 0.7).
Thirteen participants reported being ‘in flare’ (not
sure = 5), and the sample included a range of phenotypes
and domains of disease activity (Table 2).
Sixty-three important outcomes from treatment were
identified, ranging from specific (e.g. difficulty with grip)
to overarching (e.g. well-being); however, it should be
noted that these were not 63 distinct outcomes. The range
in the scale and specificity of the outcomes meant that
some were conceptually related or overlapping, for exam-
ple pain affecting specific parts of the body and being in
pain generally. These 63 outcomes were grouped into 18
subthemes, then four main themes (Table 3).
Findings are evidenced with data excerpts, followed by
participant ID, age (in years), and focus group number.
3.1 Theme 1: Symptom Alleviation
The alleviation or reduction of the physical symptoms
experienced on a regular basis was one of the most
important outcomes of treatment for participants.
Pain throughout the body Participants described pain in
their joints (including hands, wrists, feet, hips and knees),
their muscles (in particular shoulders) and their back. They
also discussed painful tenderness, for example in tendons at
the back of the foot.
‘‘I get pain in various joints round my body at dif-
ferent times’’ [Dave, 71, FG5]
‘‘I seem to have it [pain] all over my body, mainly it’s
my feet, my knees, legs’’ [Mel, 52, FG6]
While some participants found that treatments con-
trolled their pain, others always had some level of pain
present.
‘‘I’m always in pain it’s just how much’’ [Mark, 28,
FG1]
Physical and mental fatigue Fatigue emerged clearly as
a symptom that patients found a challenge to manage.
Physical exhaustion was a major component, but some
patients also experienced mental and emotional fatigue.
‘‘The most important thing is tiredness, just feeling I
can sleep at any time’’ [Louise, 48, FG5]
‘‘It’s as if your brain’s fatigued, you know, it’s as if
it’s something else, it’s not just tired, it’s beyond
that’’ [Judith, 65, FG8]
‘‘I feel so drained, so washed out, I can’t be both-
ered’’ [Ameila, 75, FG8]
Several participants identified fatigue was particularly
important because it was not alleviated by their current
treatments.
Table 1 Topic guide
Key questions in focus groups
Which symptoms have the most effect on your well-being?
What do you want from your treatment?
What are the benefits and drawbacks of treatment for you
personally?
How do you know when you are in a flare?
Table 2 Sampling framework:
number of participants with
characteristic types of PsA and
affected parts of the body
PsA phenotypes
Polyarthritis (30) Oligoarthritis (9) Distal interphalangeal (18) Axial (8) Mutilans (1)
Domains of disease activity
Skin (34) Joints (36) Spine (7) Eye (2) Enthesitisa (14)
PsA psoriatic arthritis
a Inflammation at tendon, ligament or joint capsule insertions
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‘‘The more the disease is controlled by the drugs, the
more the fatigue is a problem’’ [Adam, 41, FG3]
Itching, flaking skin: For participants with visible pso-
riasis, the symptom was associated with discomfort and
embarrassment.
‘‘The psoriasis side of it is a big part for me … it’s
not even really the response of other people it’s your
perception of it …
Yeah exactly …
You feel horrible and scabby’’ [Paul, 50; Andrew, 72;
and Miriam, 50, FG4]
Skin improvement was an important treatment target,
with several participants explaining that their PsA medi-
cations effectively controlled their psoriasis.
‘‘It was itchy and unsightly but not all that long after
I started the medication it disappeared’’ [Natalie, 68,
FG1]
Inflammation, swelling and stiffness Participants
highlighted inflamed, swollen and stiff joints as debili-
tating and therefore important to address through
treatment.
‘‘Inflammation just generally runs your body down
anyway, your body constantly fighting and stuff’’
[Duncan, 56, FG6]
‘‘It’s these two joints [in hands] that are the worst
and they’ve just become very swollen, incredibly
tender, very stiff’’ [Alison, 66, FG5]
Reducing variability Flares of disease activity were
practically and psychologically challenging. In George’s
case, he was not convinced that treatment was having a
beneficial effect on his PsA until he stopped taking it and
his symptoms returned. For Nicky, the sudden, aggressive
flare of disease activity was alarming. Consequently,
reducing symptom variability became important alongside
reducing severity.
‘‘I had to leave the medication off for about three
months and then I realised the medication was
working because then the flare ups began’’ [George,
70, FG2]
‘‘Overnight it was just out of control and I did
manage to get an appointment and had bloods taken
and then my inflammation had just gone sky high’’
[Nicky, 50, FG4]
3.2 Theme 2: Reduction of Disease Impact
While participants’ experiences of symptoms and taking
treatments varied, there was widespread agreement that an
important outcome was to reduce the impact of PsA on
their daily lives.
Overwhelming tiredness and pain Reducing disease
impact was closely related to symptom alleviation. Fatigue
and pain caused a major impact on daily life and mood if
they were not controlled.
‘‘You’re continuously drained during the day, and
you can’t concentrate on whatever you’re trying to
Table 3 Main themes and
subthemes
Main theme Subtheme
Symptom alleviation Pain throughout the body
Physical and mental fatigue
Itching, flaking skin
Inflammation, swelling and stiffness
Reducing variability
Reduction of disease impact Overwhelming tiredness and pain
Limited mobility and dexterity
Deteriorating physical fitness
Poor quality and disrupted sleep
Negative emotional responses
Strained relationships and social interactions
Improved prognosis Slowing down or halting disease progression
Enabling independence to be maintained
Enhancing quality of life, well-being and sense of normality
Minimisation of harm and burden Nausea and sickness
Concerns about long-term effects
Modes of administration
Monitoring requirements
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do, whether it’s driving, working, walking, anything’’
[Siddiq,39, FG6]
‘‘The pain and the consequences of the pain in terms
of immobility, in terms of moods and depressions, and
feeling low and so on’’ [Andrew, 72, FG4]
Limited mobility and dexterity A reduction in physical
functioning, such as walking and strength and precision of
grip, could have a significant impact. Restoring mobility
and dexterity were therefore important treatment outcomes.
‘‘It’s lack of mobility that affected me and standing
out therefore in the work place, having people stop at
the bottom of the stairs to let you up or down and just
not being normal’’ [Miles, 61, FG8]
‘‘I have it in my thumb, which is annoying, because
I’m an artist, and when it’s stiff I get frustrated
because I can’t quite do what I used to’’ [Claire, 44,
FG3]
Deteriorating physical fitness Among the losses dis-
cussed were physical fitness and enjoyment of sport and
exercise. Closely related was the unwanted consequence of
weight gain.
‘‘I was quite a fitness freak, I used to go running, go
to the gym, I had a very, very active life. I miss that’’
[Kate, 61, FG2]
‘‘When I’m not well I can’t cycle and then I start
putting on weight’’ [Janet, 65, FG1]
Poor-quality and disrupted sleep Participants described
how joint pain and stiffness impacted on their quality of
sleep, with many unable to find effective treatments.
‘‘The discomfort because that hip, that shoulder, my
back, and you see you just don’t have a good night’s
sleep, ever’’ [Joanna, 57, FG4]
‘‘Nothing seems to work, so lack of sleep is becoming
vital now’’ [Sue, 75, FG5]
Negative emotional responses The consequences of
living with PsA, characterised by pain and fatigue and
requiring ongoing management, could evoke negative
emotional responses, including low mood, depression,
anger and frustration.
‘‘I’m treated for anxiety and depression as well
because of lack of sleep basically and constantly
being in pain and run down’’ [Justin, 44, FG6]
‘‘I do feel like it’s affected my emotion, I’ve become
quite angry and resentful’’ [Abby, 41, FG7]
Strained relationships and social interactions A per-
ceived lack of understanding and unrealistic expectations
of others in relation to their PsA could put a strain on
participants’ relationships and limit their social interaction.
‘‘I have to constantly explain to my work, my wife, my
children, my family, my friends why I’m not going
out, why I’m not doing this, and so yeah, that makes
me feel quite, the emotional side of that makes me
quite insular’’ [Mark, 28, FG1]
‘‘Mentally it’s massive and I find it’s hard to get other
people to recognise it as well … I was in a marriage
for 21 years and it was a big effect on that marriage’’
[Stephen, 43, FG3]
3.3 Theme 3: Improved Prognosis
In addition to focusing on alleviating symptoms and their
impact in the immediate- and short-term, participants dis-
cussed the importance of treatment providing an improved
prognosis in the medium- and long-term.
Slowing down or halting disease progression A factor
influencing many participants’ treatment decisions was the
potential for medications to slow down or halt future joint
damage. This was important for those participants who
expressed anxiety about their PsA worsening over time.
‘‘They said it will stop your disease activity so it
won’t, your bones won’t fall to bits effectively’’
[Miriam, 50, FG4]
‘‘The worry is always there that this is going to get
worse and worse’’ [Alison, 66, FG5]
Enabling independence to be maintained Increased
disability in the future concerned those participants who
placed a high value on maintaining their independence.
‘‘If I could have anything it would be independence, it
would be to be able to be as fast as everybody else, it
will be able to drive my own car, go out when I
wanted to go out, come in and lock my own front door
and not have somebody to come in to help with the
shower’’ [Judith, 67, FG8]
‘‘I live alone and I want to keep my independence’’
[Flora, 59, FG7]
Enhancing quality of life, well-being and sense of nor-
mality While participants identified specific aspects of PsA
that currently affected them, there were also overarching
outcomes that were meaningful and potentially long-term,
for example ‘well-being’. Participants consider these out-
comes as they ‘‘seek normality’’ [Paul, 50, FG4]. For Kate,
the perceived risks of treatments were outweighed by the
opportunity they offered to have an acceptable quality of life.
‘‘I have got a shorter life because of the amount of
drugs that I take, I know that it is going to restrict my
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lifestyle. I have always said I want a good quality
even though it is short; I don’t want to live until I am
90 and be curled up in a ball somewhere, I don’t want
that, I would rather keep taking the injections and
keep going [Kate, 61, FG2]
3.4 Theme 4: Minimisation of Treatment Harm
and Burden
Some participants described their pharmacological treat-
ments as ‘miraculous’, yet there were also high levels of
anxiety. Beliefs about the balance between potential ben-
efits of controlling disease activity and joint damage with
potential harm from taking medications over time influ-
enced patients’ priorities and treatment decisions.
Nausea and sickness Participants frequently described
experiencing unpleasant side effects such as nausea and
sickness in relation to their treatments.
‘‘It [methotrexate] just made me feel so dreadful and
I had every side effect … just couldn’t tolerate it …
nausea and just everything, it was awful.
I had much the same experience with methotrexate, I
just felt dreadful all day, sick, general loss of appe-
tite, lethargic’’ [Louise, 48, and Dave, 71, FG5]
While Dave was not taking any pharmacological treat-
ments at the time of the focus group as a consequence of
side effects, Louise had gone on to try Humira, which she
was tolerating well (although it was not alleviating her
troublesome fatigue). Another side effect that caused
anxiety was lowered immunity to infection. Stuart descri-
bed ‘‘resisting’’ DMARDs and taking Naproxen only.
‘‘What the methotrexate can do, it can affect your
immune system down a bit, and I feel I could be
undoing all the good that they’re trying to do at
haematology by taking it’’ [Stuart, 60, FG7].
Concerns about long-term effects Some participants
expressed concerns about the long-term effects and possi-
ble toxicity of pharmacological treatments, and believed
that medication might cause more damage than their PsA.
‘‘Just the thought of taking more medication and
taking that long term, that bit worries me’’ [Claire,
44, FG3]
‘‘I think you could be doing yourself more harm than
good at times by taking these drugs’’ [Michael, 69, FG5]
Modes of administration Practical difficulties in relation
to self-injecting, getting tablets out of packaging or bottles,
and swallowing large numbers of tablets or large-sized
tablets were identified as barriers to taking medicines.
‘‘I really don’t want to do my injection, or when I was
taking the tablets, I don’t really want to gag’’ [Janet,
65, FG1]
Monitoring requirements The burden of adhering to
monitoring requirements was too much for some partici-
pants, who found accessing services at the appropriate time
incompatible with other commitments.
‘‘Access to the monitor side of it was part of the
reason I stopped [treatment] because it didn’t suit my
personal circumstances’’ [Chris, 44, FG2]
4 Discussion
The primary concern of participants was the ability of
treatments to alleviate symptoms and, in turn, reduce the
negative impact of disease. Pain was an unsurprising out-
come and one that is widely measured [20]; however,
fatigue and its impact featured heavily in discussions.
Although fatigue is increasingly recognised as a symptom
of PsA, it is not routinely addressed in either research or
clinical practice. Participants’ accounts of the ineffective-
ness of some treatments to ameliorate fatigue highlight the
potential for nonpharmacological approaches. In rheuma-
toid arthritis, for example, a randomised controlled trial
based on cognitive behavioural therapy was shown to
effectively reduce the impact of fatigue [21]. If patients
evaluate their treatment success on such outcomes, then
unless professionals measure these, there is the potential
for a mismatch as to how ‘treatment success’ is defined,
which might affect decisions on treatment escalation or
discontinuation. Understanding patient values will also
help clinicians and researchers target specific issues that
are undertreated.
These data provide insight into experiences and views
likely to influence patients’ treatment decisions. They
support evidence that nonadherence is consistently asso-
ciated with psychological factors (including greater treat-
ment concerns, lower treatment self-efficacy [i.e.
confidence in one’s ability to follow treatment] and
depression) and contextual factors (including practical
barriers and a suboptimal patient–clinician relationship),
many of which are modifiable risk factors [22]. Early
diagnosis of PsA, management of disease progression, and
management of impact through patient involvement in
management plans are areas of clinical care identified as
requiring improvement [23]. Our study findings strongly
support this.
Some of these outcomes, for example those relating to
adverse effects and drug safety, are routinely measured and
will continue to be so. In addition to the interrelated and
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overlapping nature of some outcomes, these data present
conceptual and measurement challenges. This includes the
difficulty of distinguishing between symptoms and their
impact and unpicking cause and effect; for example, it is
possible that negative emotional responses were a symp-
tom of high circulating levels of inflammatory cytokines
associated with active PsA which are known to induce
depressive-like behaviours, rather than a response to pain.
However, the guiding principle when grouping outcomes
into themes was to present patients’ experiences and
beliefs. In taking this approach, we found that our data
support the concept of the impact triad when considering
the implications for measurement. The impact triad pro-
poses that we need to capture severity, personal importance
and self-management of symptoms to characterise the
personal life impact of rheumatic diseases [24]. One
example of measures that have done this is the Bristol
Rheumatoid Arthritis Fatigue Scales (BRAFs) [25, 26].
These include the multidimensional BRAF-MDQ, which
captures Living with Fatigue, Physical Fatigue, Emotional
fatigue, and Cognitive Fatigue; and three BRAF Numerical
rating Scales (BRAF NRS), which capture Severity, Cop-
ing, and Effect. The ability to measure patients’ experi-
ences of fatigue and its impact in this way is potentially
important for understanding individual responses and tai-
loring interventions and treatment.
Another conceptual and measurement challenge is the
variation in the language used (e.g. participants’ own
words), which might reflect different ways of expressing
similar outcomes. At this stage, it was important to stay
close to participants’ data to identify important outcomes
and minimise imposing the research team’s interpretation
beyond grouping related outcomes as part of the inductive
analysis. However, it is neither feasible nor desirable to
measure all 63 outcomes, and further work also needs to
establish if these UK data reflect the patient perspective
internationally. These themes and subthemes were
reviewed alongside summary data generated from a study
involving 50 PsA patients in focus groups in Australia,
Brazil, France, The Netherlands, Singapore, and the US.
The two datasets were largely similar, and combined data
from both studies have been taken forward to seek inter-
national patient and physician consensus for an updated
PsA Core Domain Set [27].
4.1 Strengths and Limitations
The involvement of patient research partners (JL and CB),
as well as the use of a maximum variation sampling
approach, has increased the likelihood that findings are
relevant to a large number of patients with PsA. In addi-
tion, the cofacilitators (ED and SH) adopted an inductive
approach to data collection and analysis. Therefore,
findings reflect the patient perspective on important out-
comes, without being heavily influenced by the assump-
tions of clinicians and researchers. A limitation relates to
focus groups as a method of data collection. In a group
setting, there is the potential for some participants to feel
less able to express their point of view than others; how-
ever, there were sufficient focus groups to explore the same
topics with different participants. In addition, the cofacil-
itators intervened to include participants if they perceived
an imbalance or dominance of a single viewpoint.
5 Conclusion
Qualitative data captured important outcomes of treatment
from the perspective of patients with PsA. Over 60 out-
comes were identified and grouped into four themes. These
highlight the symptoms that most affect patients, the
impact these can have on their daily lives, the patients’
anxieties and concerns in relation to pharmacological
treatments, and their expectations about benefits and long-
term prognosis. There is a need to establish how identified
outcomes are represented in existing measures to ensure
the inclusion of the patient perspective in future research
and clinical practice. Research is also needed to understand
patients’ treatment beliefs and the role of the clinical team
in communicating treatment-related information.
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